The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Cardiovascular Side Effects of Diethylstilbestrol, Cyproterone Acetate, Medroxyprogesterone Acetate and Estramustine Phosphate Used for the Treatment of Advanced Prostatic Cancer: Results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762
Abstract
Two randomized trials were started in 1976 by the European Organization for Research on Treatment of Cancer urological group. Trial 30761 compared 1 mg. diethylstilbestrol orally 3 times daily to 250 mg. oral cyproterone acetate daily and to 500 mg. medroxyprogesterone acetate intramuscularly 3 times weekly for 8 weeks, then 200 mg. orally daily. Trial 30762 compared 3 mg. diethylstilbestrol to 560 mg. estramustine phosphate orally for 8 weeks and then 280 mg. daily. The 239 patients in study 30761 and 226 in study 30762 were evaluated for cardiovascular toxicity during treatment. Various types of side effects (fluid retention, hypertension, electrocardiographic changes, myocardial infarction and thromboembolic disease) and their degrees of severity were analyzed. In both studies the most frequent type of cardiovascular toxicity was represented by fluid retention. Cardiovascular toxicity as a whole was higher with diethylstilbestrol than with estramustine phosphate or medroxyprogesterone acetate therapy, and was the lowest with cyproterone acetate therapy. The risk of severe cardiovascular complications developing was the highest during the first 6 months of treatment. Increasing age, body weight greater than 75 kg. and, especially, the presence of previous cardiovascular disease represented adverse factors in the development of cardiovascular toxicity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
All three agents (progestogens, antiandrogens, GnRH analogues) are associated with potential adverse effects such as precipitation or aggravation of cardiac conditions, gynaecomastia, weight gain, hot flushes, or depression.
“All three agents are associated with potential adverse effects (Reilly 2000), such as precipitation or aggravation of cardiac conditions (De Voogt 1986; Pierce 1995), gynaecomastia, weight gain, hot flushes, or depression (Grubin 2008).”
From Pharmacological interventions for those who have sexually offended or are at risk of offending (2015) · cites this paper as De Voogt 1986
Citations
Cites
Use of Ranks in One-Criterion Variance Analysis
Kruskal, W. H., & Wallis, W. A. (1952) · Journal of the American Statistical Association · doi:10.1080/01621459.1952.10483441 · Cited by 13,912
Flagged first, then by citations
Research works printed but not linked: 11
- Pavone-Macaluso, 1980, EORTC protocols in prostatic cancer. An interim report, Scand. J. Urol. Nephrol., 55, 163
- Pavone-Macaluso, 1983, Medroxyprogesterone acetate in the treatment of prostatic cancer: preliminary results of EORTC trial 30761 comparing medroxyprogesterone acetate with stilbestrol and with cyproterone acetate, vol. 2, 183
- Sylvester, 1980, On the analysis of response rates in studies of advanced disease, Eur. J. Cancer, 16, 5
- Gehan, 1969, Estimating survival functions from the life table, J. Chron. Dis., 21, 629, 10.1016/0021-9681(69)90035-6 · DOI
- Smith, 1970, A computer program for estimating survival functions from the life table, Comput. Prog. Biomed., 1, 58, 10.1016/0010-468X(70)90014-0 · DOI
- 1967, The Veterans Administration Cooperative Urological Research Group: Carcinoma of the prostate: treatment comparisons, J. Urol., 98, 516, 10.1016/S0022-5347(17)62926-4 · DOI
- Byar, 1973, The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate, Cancer, 32, 1126, 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C · DOI
- Byar, 1980, Review of the Veterans Administration studies of cancer of the prostate and new results concerning treatment of stage I and II tumors, 471
- Shearer, 1973, Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer, Brit. J. Urol., 45, 668, 10.1111/j.1464-410X.1973.tb12238.x · DOI
- Gordon, 1974, Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico, J. Chron. Dis., 27, 329, 10.1016/0021-9681(74)90013-7 · DOI
- 1982, The Italian Research Group of the Seven Countries study: Incidence and prediction of coronary heart disease in two Italian rural population samples followed-up for 20 years, Acta Cardiol., 37, 129
Cited by
Sorted by citations
Pharmacological interventions for those who have sexually offended or are at risk of offending
Khan, O., Ferriter, M., Huband, N., Powney, M. J., Dennis, J. A., & Duggan, C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007989.pub2 · Cited by 144
Metadata
- Authors
- de Voogt, H. J., Smith, P. H., Pavone-Macaluso, M., de Pauw, M., Suciu, S., & Members of the European Organization for Research on Treatment of Cancer Urological Group
- Affiliations
- St James's University Hospital (GB)
- From the Free University, Amsterdam, The Netherlands
- Venue
- Journal of Urology
- Published
- 1986-02
- Volume
- 135
- Issue
- 2
- Pages
- 303-307
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W38359027
- Cited by
- 186
- References
- 1
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2020: 4 · 2019: 1 · 2017: 4 · 2016: 1 · 2015: 4 · 2014: 3 · 2013: 4 · 2012: 7
- FWCI
- 16.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (5R10CA11488-11)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- advanced prostate cancer, cardiotoxicity, diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate, estramustine phosphate, fluid retention, hypertension, electrocardiographic changes, myocardial infarction, thromboembolism, risk factors, androgen deprivation therapy
- MeSH terms
- Aged, Body Weight, Cardiovascular Diseases, Clinical Trials as Topic, Cyproterone, Diethylstilbestrol, Estramustine, Europe, Humans, Male, Medroxyprogesterone, Middle Aged, Nitrogen Mustard Compounds, Prostatic Neoplasms, Random Allocation, Time Factors, Medroxyprogesterone Acetate, Cyproterone Acetate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
